[图书][B] T Cell Based Immunotherapy Targeting Fibroblast Growth Factor Receptor 4 as a Therapeutic Against Rhabdomyosarcoma
N Shivaprasad - 2019 - search.proquest.com
Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma of childhood, has a low
mutational burden with few actionable somatic targets. Fibroblast growth factor receptor 4 …
mutational burden with few actionable somatic targets. Fibroblast growth factor receptor 4 …
[HTML][HTML] Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure
rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase …
rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase …
[HTML][HTML] Novel FGFR4-targeting single-domain antibodies for multiple targeted therapies against rhabdomyosarcoma
N Alijaj, S Moutel, ZL Gouveia, M Gray, M Roveri… - Cancers, 2020 - mdpi.com
Simple Summary Rhabdomyosarcoma (RMS) accounts for more than 50% of all soft tissue
sarcomas in childhood and adolescence. Despite progress and intensified multimodality …
sarcomas in childhood and adolescence. Despite progress and intensified multimodality …
649. Developing FGFR4 Chimeric antigen receptor CAR T cell therapy against Rhabdomyosarcoma
N Shivaprasad, Y Xiong, M Yohe, D Schneider… - Molecular Therapy, 2016 - cell.com
In recent years, adoptive cell therapy using T cells engineered with chimeric antigen
receptors (CAR T) specific for CD19 has shown marked clinical efficacy. Nevertheless …
receptors (CAR T) specific for CD19 has shown marked clinical efficacy. Nevertheless …
Abstract LB213: Potent antitumor activity of a FGFR4 CAR-T in rhabdomyosarcoma
ATC Cheuk, M Tian, N Shivaprasad, S Highfill… - Cancer Research, 2022 - AACR
Rhabdomyosarcoma (RMS) is an aggressive soft tissue sarcoma originating from skeletal
muscle in children and adolescent young adults. Despite multi-modal aggressive therapies …
muscle in children and adolescent young adults. Despite multi-modal aggressive therapies …
[HTML][HTML] CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma
Chimeric antigen receptor (CAR) T-cells targeting Fibroblast Growth Factor Receptor 4
(FGFR4), a highly expressed surface tyrosine receptor in rhabdomyosarcoma (RMS), are …
(FGFR4), a highly expressed surface tyrosine receptor in rhabdomyosarcoma (RMS), are …
FGFR4-targeted Chimeric antigen receptors combined with anti-myeloid polypharmacy effectively treat orthotopic Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue cancer in children. Treatment
outcomes, particularly for relapsed/refractory or metastatic disease, have not improved in …
outcomes, particularly for relapsed/refractory or metastatic disease, have not improved in …
Development of FGFR4-targeted chimeric antigen receptors (CARs) for the treatment of rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle, and is the
most common soft tissue cancer in children. Patients with metastatic RMS have a poor …
most common soft tissue cancer in children. Patients with metastatic RMS have a poor …
FGFR4 as a potential therapeutic target for monoclonal antibody based intervention in rhabdomyosarcoma
S Baskar, N Shivaprasad, Z Zhu, D Dimitrov, M Sigrist… - Cancer Research, 2015 - AACR
Background: Rhabdomyosarcoma (RMS) is most common soft tissue sarcoma in childhood
and adolescence. There are two major subtypes of RMS-alveolar RMS (ARMS) and …
and adolescence. There are two major subtypes of RMS-alveolar RMS (ARMS) and …
FGFR4 and CD276 dualtargeting CAR-T cells for treating rhabdomyosarcoma and other solid tumors
Background: Chimeric antigen receptor T-cell therapies (CAR-T) have shown success in
treating refractory and relapsed leukemia and lymphoma, while they perform poorly in solid …
treating refractory and relapsed leukemia and lymphoma, while they perform poorly in solid …